Ghrelin Attenuates the Inhibitory Effects of Glucagon-Like Peptide-1 and Peptide YY(3-36) on Food Intake and Gastric Emptying in Rats
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Ghrelin stimulates, while glucagon-like peptide-1 (GLP-1) and peptide YY(3-36) [PYY(3-36)] inhibit, food intake and gastric emptying in rats. We determined the dose-dependent effects of a 3-h intravenous infusion of ghrelin at dark onset on food intake in freely feeding rats, and on the inhibitory effects of intravenous infusion of GLP-1 and PYY(3-36) on food intake and gastric emptying. Ghrelin (150 pmol · kg−1 · min−1) stimulated food intake by 28% during the infusion period primarily by increasing meal frequency; doses of 15 and 50 pmol · kg−1 · min−1 had no effect. GLP-1 (15 pmol · kg−1 · min−1) inhibited food intake by 35–54%; coinfusion of ghrelin at 50 and 150 pmol · kg−1 · min−1 attenuated this effect by 60 and 64%, respectively. PYY(3-36) (15 pmol · kg−1 · min−1) inhibited food intake by 32%; ghrelin at 15 and 50 pmol · kg−1 · min−1 attenuated this effect by 54 and 74%, respectively. A 20-min intravenous infusion of ghrelin (15–150 pmol · kg−1 · min−1) attenuated GLP-1–and PYY(3-36)-induced inhibition of gastric emptying of saline by 6–29%. Thus, intravenous infusion of ghrelin during the early dark period stimulates food intake in freely feeding rats by increasing meal frequency, and similar doses of ghrelin attenuate gastric emptying and feeding responses to GLP-1 and PYY(3-36). These results suggest that ghrelin may stimulate food intake in part by attenuating the inhibitory effects of GLP-1 and PYY(3-36) on gastric emptying and food intake.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans
Cummings, D. E., Purnell, J. Q., Frayo, R. S., Schmidova, K., Wisse, B. E., & Weigle, D. S. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1714 · Cited by 2,940 · cited 8×
“A 20-min intravenous infusion of ghrelin (15–150 pmol kg 1 min (1)) attenuated GLP-1– and PYY(3-36)-induced inhibition of gastric emptying of saline by 6–29%.”
BackgroundInfluentialBiological, Physiological, Pathophysiological, and Pharmacological Aspects of Ghrelin
van der Lely, A. J., Tschöp, M., Heiman, M. L., & Ghigo, E. (2004) · Endocrine Reviews · doi:10.1210/er.2002-0029 · Cited by 1,187
Drazen, D. L., Vahl, T. P., D’Alessio, D. A., Seeley, R. J., & Woods, S. C. (2006) · Endocrinology · doi:10.1210/en.2005-0973 · Cited by 334
Cited by
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
The role of incretins in glucose homeostasis and diabetes treatment
Kim, W., & Egan, J. M. (2008) · Pharmacological Reviews · doi:10.1124/pr.108.000604 · Cited by 824
“In addition, ghrelin (Chelikani et al., 2006) and leptin (Goldstone et al., 1997; Goldstone et al., 2000) may exert their effects on food intake at least in part through attenuating or enhancing the effects of GLP-1, respectively.”
BackgroundKaramanakos, S. N., Vagenas, K., Kalfarentzos, F., & Alexandrides, T. K. (2008) · Annals of Surgery · doi:10.1097/sla.0b013e318156f012 · Cited by 813
Obesity in Type 1 Diabetes: Pathophysiology, Clinical Impact, and Mechanisms
Corbin, K. D., Driscoll, K. A., Pratley, R. E., Smith, S. R., Maahs, D. M., Mayer-Davis, E. J., & Advancing Care for Type 1 Diabetes and Obesity Network (ACT1ON) (2018) · Endocrine Reviews · doi:10.1210/er.2017-00191 · Cited by 262
The metabolic role of vagal afferent innervation
Waise, T. M. Z., Dranse, H. J., & Lam, T. K. T. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0062-1 · Cited by 140
Metadata
- Authors
- Chelikani, P. K., Haver, A. C., & Reidelberger, R. D.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2006-11-01
- Volume
- 55
- Issue
- 11
- Pages
- 3038-3046
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2144650258
- Cited by
- 50
- References
- 3
- FWCI
- 2.21
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.